Gut Microbes Reports,
Journal Year:
2024,
Volume and Issue:
1(1), P. 1 - 16
Published: Dec. 18, 2024
Gut
microbiota
in
non-celiac
gluten
sensitivity
(NCGS)
has
been
poorly
studied
for
its
involvement
the
disorder
and
site
specificity.
We
investigated
small
intestinal,
large
intestinal
stool
profiles
patients
with
NCGS
highly
overlapping
irritable
bowel
syndrome
(IBS)
as
well
effect
of
gluten-free
diet
(GFD)
on
NCGS.
True
were
recruited
based
serological
response
anti-gliadin
antibodies,
6-week
free
symptom
recurrence
gluten-rechallenge.
Analyses
using
16S
rRNA
gene
amplicon
shotgun
sequencing
revealed
community
differences
core
microbiome
diversity
measures
across
sample
types
indicating
dysbiosis
mainly
mucosa-associated
patients.
Genera
Elusimicrobiaum,
Succinivibrio,
Bacillus
Alcaligenes
appeared
signatures
intestine
Presence
differential
taxa
co-occurring
at
sampling
sites,
enabled
recognition
site-specific
microbial
signatures.
GFD
led
to
a
shift
microbiome.
Metagenome
analysis
subtle
pathways
amino
acid
biosynthesis
including
L-ornithine.
Mucosa-associated
structure
was
quite
distinct
comparison
that
IBS.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(14), P. 7937 - 7937
Published: July 20, 2024
The
gut
microbiota
has
acquired
significant
attention
in
recent
years
for
its
potential
as
a
diagnostic
biomarker
colorectal
cancer
(CRC).
In
this
literature
review,
we
looked
at
the
studies
exploring
alterations
composition
associated
with
CRC,
mechanisms
linking
dysbiosis
to
CRC
development,
and
approaches
utilizing
analysis.
Our
research
led
conclusion
that
individuals
often
display
their
compared
healthy
individuals.
These
can
include
changes
diversity,
abundance,
type
of
bacteria
present
gut.
While
use
holds
promise,
further
is
needed
validate
effectiveness
standardize
testing
protocols.
Additionally,
considerations
such
variability
among
factors
must
be
addressed
before
microbiota-based
tests
widely
implemented
clinical
practice.
Journal of Translational Medicine,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: Oct. 15, 2024
The
tumour
microenvironment
represents
a
novel
frontier
in
oncological
research.
Over
the
past
decade,
accumulating
evidence
has
underscored
importance
of
(TME),
including
cells,
stromal
immune
and
various
secreted
factors,
which
collectively
influence
growth,
invasion,
responses
to
therapeutic
agents.
Immune
cells
within
TME
are
now
widely
acknowledged
play
pivotal
roles
development
treatment.
While
some
perspectives
have
posited
that
facilitate
progression
confer
resistance
interventions,
contrasting
conclusions
also
exist.
Affirmative
negative
appear
be
context
dependent,
unified
consensus
yet
reached.
burgeoning
body
research
on
relationship
between
gut
microbiota
tumours
recent
years
led
growing
understanding.
Most
studies
indicated
specific
components
microbiota,
such
as
unique
bacterial
communities
or
secretory
diverse
regulating
TME,
thereby
influencing
prognosis
outcomes
cancer
treatments.
A
detailed
understanding
these
factors
could
provide
insights
into
therapy.
In
this
study,
we
aimed
synthesise
information
interactions
providing
an
in-depth
exploration
potential
guiding
implications
for
future
therapies.
Heliyon,
Journal Year:
2024,
Volume and Issue:
10(15), P. e35336 - e35336
Published: July 27, 2024
Gastrointestinal
(GI)
cancers
represent
a
significant
global
health
challenge,
driving
relentless
efforts
to
identify
innovative
diagnostic
and
therapeutic
approaches.
Recent
strides
in
microbiome
research
have
unveiled
previously
underestimated
dimension
of
cancer
progression
that
revolves
around
the
intricate
metabolic
interplay
between
GI
host's
gut
microbiota.
This
review
aims
provide
comprehensive
overview
these
emerging
interactions
their
potential
catalyze
paradigm
shift
precision
diagnosis
breakthroughs
cancers.
The
article
underscores
groundbreaking
impact
on
oncology
by
delving
into
symbiotic
connection
host
metabolism
It
offers
valuable
insights
tailoring
treatment
strategies
individual
patients,
thus
moving
beyond
traditional
one-size-fits-all
approach.
also
sheds
light
novel
methodologies
could
transform
early
detection
cancers,
potentially
leading
more
favorable
patient
outcomes.
In
conclusion,
exploring
microbiota
showcases
promising
frontier
ongoing
battle
against
formidable
diseases.
By
comprehending
harnessing
microbiome's
influence,
future
innovation
for
appears
optimistic,
opening
doors
tailored
treatments
enhanced
precision.
Frontiers in Cellular and Infection Microbiology,
Journal Year:
2025,
Volume and Issue:
15
Published: April 17, 2025
Colorectal
cancer
(CRC)
is
a
prevalent
and
lethal
malignancy,
with
the
role
of
gut
microbiota
in
its
development
still
unclear.
This
study
examines
differences
between
CRC
patients
healthy
controls
explores
their
association
host
gene
expression
to
identify
potential
diagnostic
therapeutic
targets.
Fecal
samples
from
10
13
were
subjected
16S
rRNA
sequencing.
Transcriptome
sequencing
tumor
tissues,
normal
mucosa,
colorectal
polyps
same
was
performed
differentially
expressed
genes
(DEGs).
Pearson
correlation
analysis
employed
associate
operational
taxonomic
units
(OTUs)
expression.
β-diversity
showed
significant
(P
<
0.01).
LEfSe
identified
38
distinct
bacterial
taxa,
genera
such
as
Bacteroides,
Peptostreptococcus,
Parabacteroides
being
enriched
patients.
uncovered
1,026
DEGs.
Notably,
TIMP1
BCAT1
positively
correlated
(r
>
0.76,
P
0.01)
pathogenic
bacteria
like
Fusobacterium
nucleatum
Peptostreptococcus
stomatis.
Tumor-related
TRPM4,
MYBL2,
CDKN2A
significantly
upregulated
specific
taxa.
underscores
alterations
associated
reveals
novel
correlations
microbes
expression,
offering
markers
targets
for
CRC.
Cell Proliferation,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 27, 2024
Abstract
Given
the
growing
interest
in
metabolic
heterogeneity
of
hepatocellular
carcinoma
(HCC)
and
portal
vein
tumour
thrombus
(PVTT).
This
study
comprehensively
analysed
HCC,
PVTT,
normal
liver
samples
using
multi‐omics
combinations.
A
single‐cell
RNA
sequencing
dataset
encompassing
six
major
cell
types
was
obtained
for
integrated
analysis.
The
optimal
subtypes
were
identified
cluster
stratification
validated
spatial
transcriptomics
fluorescent
multiplex
immunohistochemistry.
Then,
a
combined
index
based
meta‐cluster
calculated
to
verify
its
prognostic
significance
data
from
public
cohorts.
Our
first
depicted
landscape
non‐malignant
cells
HCC
PVTT
at
multiomics
levels.
interpret
characteristics
formation
development.
provided
effective
predictions
prognosis
immunotherapy
responses.
Patients
with
higher
had
relatively
poor
(
p
<0.001).
We
also
found
metabolism
polyamines
key
pathway
involved
conversion
ODC1
significantly
expressed
compared
tissue
=0.03).
findings
revealed
both
consistency
PVTT.
risk
on
cancer‐associated
fibroblasts
myeloid
conduce
predict
guide
treatment.
offers
new
directions
understanding
disease
development
World Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
30(38), P. 4175 - 4193
Published: Sept. 29, 2024
As
a
research
hotspot
in
the
field
of
molecular
biology,
N6-methyladenosine
(m6A)
modification
has
made
progress
treatment
colorectal
cancer
(CRC),
leukemia
and
other
cancers.
Numerous
studies
have
demonstrated
that
tumour
microenvironment
(TME)
regulates
level
m6A
host
activates
series
complex
epigenetic
signalling
pathways
through
interactions
with
CRC
cells,
thus
affecting
progression
prognosis
CRC.
However,
diversity
composition
TME
factors,
this
action
is
reciprocal
complex.
Encouragingly,
some
experimentally
revealed
intestinal
flora
can
alter
cell
proliferation
by
directly
acting
on
thereby
altering
proliferation.
This
review
summarizes
data,
supporting
idea
influence
levels
such
as
methyl
donor
metabolism
affect
We
also
role
diagnosis,
treatment,
prognostic
assessment
discuss
current
status,
limitations,
potential
clinical
value
field.
propose
additional
in-depth
alterations
patients
their
TME-related
targeted
therapeutic
issues
will
lead
to
better
outcomes
for
patients.
